Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b,Condition 2a,Condition 2b,Condition 3a,Condition 3b 753,"Hoopes RR Jr, et al., J Am Soc Nephrol 2003 Jul;14(7):1844-50.",urine calcium amount,,RS:0000363,F344/NHsd,female,66 days to 60 days,3,,CMO:0000763,urine calcium excretion rate,,,,1.73,mg/d,0.1212,0.21,MMO:0000147,urine analysis,,86400.0,,,,,controlled calcium content diet (0.6 %) (between 4 and 10 days),67506,controlled calcium content diet (0.6 %) (between 4 and 10 days),,,,, 753,"Hoopes RR Jr, et al., J Am Soc Nephrol 2003 Jul;14(7):1844-50.",urine calcium amount,,RS:0000363,F344/NHsd,male,66 days to 60 days,3,,CMO:0000763,urine calcium excretion rate,,,,1.72,mg/d,0.1443,0.25,MMO:0000147,urine analysis,,86400.0,,,,,controlled calcium content diet (0.6 %) (between 4 and 10 days),67507,controlled calcium content diet (0.6 %) (between 4 and 10 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",heart right ventricle mass,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0000072,heart right ventricle wet weight,,,median,0.139,g,,,MMO:0000005,post excision weight measurement,,,,,,,control condition,11563,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",heart left ventricle mass,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0000071,heart left ventricle wet weight,,,median,0.536,g,,,MMO:0000005,post excision weight measurement,,,,,,,control condition,11564,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",heart right ventricle mass,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0003280,heart right ventricle weight to left ventricle plus septum weight ratio,,,median,0.25,g/g,,,MMO:0000005,post excision weight measurement,,,,,,,control condition,11565,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",heart right ventricle mass,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0000072,heart right ventricle wet weight,,,median,0.207,g,,,MMO:0000005,post excision weight measurement,,,,,,,air oxygen content (10 %) (for 21 days),11567,air oxygen content (10 %) (for 21 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",heart right ventricle mass,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0003280,heart right ventricle weight to left ventricle plus septum weight ratio,,,median,0.41,g/g,,,MMO:0000005,post excision weight measurement,,,,,,,air oxygen content (10 %) (for 21 days),11569,air oxygen content (10 %) (for 21 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",heart left ventricle mass,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0000071,heart left ventricle wet weight,,,median,0.533,g,,,MMO:0000005,post excision weight measurement,,,,,,,air oxygen content (10 %) (for 21 days),11568,air oxygen content (10 %) (for 21 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",pulmonary arterial blood pressure trait,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0000778,mean pulmonary arterial blood pressure,,,median,27,mmHg,,,MMO:0000011,vascular indwelling catheter method,pulmonary artery,0,,,,,air oxygen content (10 %) (for 21 days),11566,air oxygen content (10 %) (for 21 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",body mass,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0000012,body weight,,,median,290,g,,,MMO:0000016,body weighing method,,,,,,,control condition,11562,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",body mass,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0000012,body weight,,,median,238,g,,,MMO:0000016,body weighing method,,0,,,,,air oxygen content (10 %) (for 21 days),66124,air oxygen content (10 %) (for 21 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",arterial blood pressure trait,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0000009,mean arterial blood pressure,,,median,121,mmHg,,,MMO:0000011,vascular indwelling catheter method,left common carotid artery,0,,,,,control condition,66127,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",arterial blood pressure trait,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0000009,mean arterial blood pressure,,,median,112,mmHg,,,MMO:0000011,vascular indwelling catheter method,left common carotid artery,0,,,,,air oxygen content (10 %) (for 21 days),66128,air oxygen content (10 %) (for 21 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0000037,hematocrit,,,median,46,%,,,MMO:0000214,hematocrit analysis,,0,,,,,control condition,66131,control condition,,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",erythrocyte quantity,,RS:0000363,F344/NHsd,male,105 days,23,,CMO:0000037,hematocrit,,,median,70,%,,,MMO:0000214,hematocrit analysis,,0,,,,,air oxygen content (10 %) (for 21 days),66132,air oxygen content (10 %) (for 21 days),,,,, 102,"Zhao L et al., 2001, Circulation, 103(3), 442-7",pulmonary arterial blood pressure trait,,RS:0000363,F344/NHsd,male,105 days,12,,CMO:0000778,mean pulmonary arterial blood pressure,,,median,16,mmHg,,,MMO:0000011,vascular indwelling catheter method,pulmonary artery,0,,,,,control condition,66123,control condition,,,,, 105,"Solberg LC, et al., Physiol Genomics. 2006 Nov 27;27(3):362-9. Epub 2006 Aug 8",adrenal gland mass,,RS:0000363,F344/NHsd,female,112 days,17,,CMO:0000164,both adrenal glands wet weight,,,,51.5,mg,1.9,7.8339,MMO:0000005,post excision weight measurement,,,,,,,control condition,11603,control condition,,,,, 105,"Solberg LC, et al., Physiol Genomics. 2006 Nov 27;27(3):362-9. Epub 2006 Aug 8",adrenal gland mass,,RS:0000363,F344/NHsd,male,112 days,28,,CMO:0000164,both adrenal glands wet weight,,,,47,mg,0.9,4.7624,MMO:0000005,post excision weight measurement,,,,,,,control condition,11601,control condition,,,,, 105,"Solberg LC, et al., Physiol Genomics. 2006 Nov 27;27(3):362-9. Epub 2006 Aug 8",blood corticosterone amount,,RS:0000363,F344/NHsd,male,105 days,28,,CMO:0001173,plasma corticosterone level,,,,81,ng/ml,8.3,43.9195,MMO:0000073,radioimmunoassay,,,,,,,control condition,13120,control condition,,,,, 105,"Solberg LC, et al., Physiol Genomics. 2006 Nov 27;27(3):362-9. Epub 2006 Aug 8",blood corticosterone amount,,RS:0000363,F344/NHsd,female,105 days,17,,CMO:0001173,plasma corticosterone level,,,,94.7,ng/ml,21.2,87.4098,MMO:0000073,radioimmunoassay,,,,,,,control condition,13122,control condition,,,,, 105,"Solberg LC, et al., Physiol Genomics. 2006 Nov 27;27(3):362-9. Epub 2006 Aug 8",blood corticosterone amount,,RS:0000363,F344/NHsd,male,105 days,28,,CMO:0001173,plasma corticosterone level,,,,354.7,ng/ml,18.9,100.0094,MMO:0000073,radioimmunoassay,,0.0,,,,,physical restraint (for 0.2 hours),13126,physical restraint (for 0.2 hours),,,,, 105,"Solberg LC, et al., Physiol Genomics. 2006 Nov 27;27(3):362-9. Epub 2006 Aug 8",blood corticosterone amount,,RS:0000363,F344/NHsd,female,105 days,17,,CMO:0001173,plasma corticosterone level,,,,503.7,ng/ml,32.4,133.5886,MMO:0000073,radioimmunoassay,,0,,,,,physical restraint (for 0.2 hours),13130,physical restraint (for 0.2 hours),,,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",blood insulin amount,,RS:0000363,F344/NHsd,female,119 days,10,,CMO:0000342,plasma insulin level,,,,17,mU/l,2.4,7.5895,MMO:0000164,intraperitoneal glucose tolerance test,,0,,post glucose injection,60,min,fasting (for 16 hours) then glucose solution (2 g/kg) ,11615,fasting (for 16 hours),,glucose solution (2 g/kg) ,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",blood insulin amount,,RS:0000363,F344/NHsd,male,119 days,10,,CMO:0000342,plasma insulin level,,,,43,mU/l,4.6,14.5465,MMO:0000164,intraperitoneal glucose tolerance test,,0,,post glucose injection,60,min,fasting (for 16 hours) then glucose solution (2 g/kg) ,11613,fasting (for 16 hours),,glucose solution (2 g/kg) ,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",body mass,,RS:0000363,F344/NHsd,female,119 days,10,,CMO:0000012,body weight,,,,221,g,3.8,12.0167,MMO:0000016,body weighing method,,0,,,,,fasting (for 16 hours),11611,fasting (for 16 hours),,,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",body mass,,RS:0000363,F344/NHsd,male,119 days,10,,CMO:0000012,body weight,,,,345,g,5.4,17.0763,MMO:0000016,body weighing method,,0,,,,,fasting (for 16 hours),11609,fasting (for 16 hours),,,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",blood glucose amount,,RS:0000363,F344/NHsd,male,119 days,10,,CMO:0000042,plasma glucose level,,,,131.6,mg/dl,3.0,9.4868,MMO:0000164,intraperitoneal glucose tolerance test,,0,,post glucose injection,60,min,fasting (for 16 hours) then glucose solution (2 g/kg) ,13176,fasting (for 16 hours),,glucose solution (2 g/kg) ,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",blood glucose amount,,RS:0000363,F344/NHsd,male,119 days,10,,CMO:0000042,plasma glucose level,,,,88,mg/dl,3.1,9.8031,MMO:0000315,plasma glucose analysis,,0,,,,,fasting (for 16 hours) then glucose solution (2 g/kg) ,13177,fasting (for 16 hours),,glucose solution (2 g/kg) ,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",blood glucose amount,,RS:0000363,F344/NHsd,male,105 days,10,,CMO:0000042,plasma glucose level,,,,117.7,mg/dl,2.7,8.5381,MMO:0000315,plasma glucose analysis,,0,,,,,physical restraint in tube type rodent restrainer (for 0.5 hours),13178,physical restraint in tube type rodent restrainer (for 0.5 hours),,,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",blood glucose amount,,RS:0000363,F344/NHsd,female,105 days,10,,CMO:0000042,plasma glucose level,,,,102.2,mg/dl,4.0,12.6491,MMO:0000315,plasma glucose analysis,,0,,,,,physical restraint in tube type rodent restrainer (for 0.5 hours),13179,physical restraint in tube type rodent restrainer (for 0.5 hours),,,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",blood glucose amount,,RS:0000363,F344/NHsd,female,105 days,10,,CMO:0000042,plasma glucose level,,,,121.7,mg/dl,5.1,16.1276,MMO:0000164,intraperitoneal glucose tolerance test,,0,,Post glucose injection,60,min,fasting (for 16 hours) then glucose solution (2 g/kg) ,13180,fasting (for 16 hours),,glucose solution (2 g/kg) ,,, 107,"Solberg Woods LC, et al., Mamm Genome. 2009 Aug 22",blood glucose amount,,RS:0000363,F344/NHsd,female,119 days,10,,CMO:0000042,plasma glucose level,,,,65.1,mg/dl,3.6,11.3842,MMO:0000315,plasma glucose analysis,,0,,,,,fasting (for 16 hours) then glucose solution (2 g/kg) ,13181,fasting (for 16 hours),,glucose solution (2 g/kg) ,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",blood hemoglobin amount,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000026,blood hemoglobin level,,,,13.8,g/dl,0.9192,2.6,MMO:0000146,automated blood cell counting method,,0.0,Anilytics,,,,control condition,13161,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",erythrocyte quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000037,hematocrit,,,,37.6,%,2.7577,7.8,MMO:0000179,automated blood analysis,,0.0,Anilytics,,,,control condition,13165,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",erythrocyte size trait,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000038,mean corpuscular volume,,,,52,fl,0.2475,0.7,MMO:0000179,automated blood analysis,,0.0,Anilytics,,,,control condition,13170,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",blood hemoglobin amount,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,36.7,g/dl,0.6364,1.8,MMO:0000179,automated blood analysis,,0.0,Anilytics,,,,control condition,13172,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",erythrocyte quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000025,red blood cell count,,,,0.00728,x 10E6 cells/ul,5.0E-4,0.0015,MMO:0000179,automated blood analysis,,0.0,Anilytics,,,,control condition,68376,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",leukocyte quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000365,total white blood cell count,,,,10.9,x 1000 cells/ul,1.5203,4.3,MMO:0000179,automated blood analysis,blood,0.0,Anilytics,,,,control condition,68378,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",neutrophil quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000030,blood neutrophil count,,,,2.72,x 1000 cells/ul,0.3536,1.0,MMO:0000179,automated blood analysis,heart or retroorbital sinus,0.0,Anilytics,,,,control condition,68380,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",lymphocyte quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000031,blood lymphocyte count,,,,6.75,x 1000 cells/ul,0.9192,2.6,MMO:0000179,automated blood analysis,blood,0.0,Anilytics,,,,control condition,68382,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",monocyte quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000032,blood monocyte count,,,,0.51,x 1000 cells/ul,0.1414,0.4,MMO:0000179,automated blood analysis,blood,0.0,Anilytics,,,,control condition,68384,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",eosinophil quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000033,blood eosinophil count,,,,0.28,x 1000 cells/ul,0.0707,0.2,MMO:0000179,automated blood analysis,blood,0.0,Anilytics,,,,control condition,68386,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",basophil quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0000034,blood basophil count,,,,0.64,x 1000 cells/ul,0.2121,0.6,MMO:0000179,automated blood analysis,blood,0.0,Anilytics,,,,control condition,68388,control condition,,,,, 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",neutrophil quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,14,,CMO:0001431,inflammatory exudate neutrophil count,,,,23.2,x 10E6 cells/ml,2.4,8.98,MMO:0000368,hemocytometer,subcutaneous interscapular cavity,0.0,hemocytometer,,,,room temperature (14 ml) (for 3 days) then room temperature (10 ml) (for 3 days) then carrageenan (1 ml) (for 6 hours),68394,room temperature (14 ml) (for 3 days),,room temperature (10 ml) (for 3 days),,carrageenan (1 ml) (for 6 hours), 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",leukocyte quantity,,RS:0000363,F344/NHsd,female,98 days to 56 days,14,,CMO:0001432,inflammatory exudate mononuclear leukocyte count,,inflammatory air pouch exudate mononuclear cell count,,3.8,x 10E6 cells/ml,0.4,1.4967,MMO:0000368,hemocytometer,subcutaneous interscapular cavity,0.0,hemocytometer,,,,room temperature (14 ml) (for 3 days) then room temperature (10 ml) (for 3 days) then carrageenan (1 ml) (for 6 hours),68396,room temperature (14 ml) (for 3 days),,room temperature (10 ml) (for 3 days),,carrageenan (1 ml) (for 6 hours), 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",tumor necrosis factor amount,,RS:0000363,F344/NHsd,female,98 days to 56 days,9,,CMO:0001435,inflammatory exudate tumor necrosis factor level,,inflammatory air pouch exudate Tnf level,,809,pg/ml,143.0,429.0,MMO:0000075,enzyme linked immunosorbent assay,subcutaneous interscapular cavity,0.0,hemocytometer,,,,room temperature (14 ml) (for 3 days) then room temperature (10 ml) (for 3 days) then carrageenan (1 ml) (for 6 hours),68400,room temperature (14 ml) (for 3 days),,room temperature (10 ml) (for 3 days),,carrageenan (1 ml) (for 6 hours), 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",nitric oxide amount,,RS:0000363,F344/NHsd,female,98 days to 56 days,10,,CMO:0001436,inflammatory exudate nitric oxide level,,inflammatory exudate nitric oxide measurement,median,0.115,umol/l,,,MMO:0000329,liquid phase colorimetry,subcutaneous interscapular cavity,0.0,Griess test,,,,room temperature (14 ml) (for 3 days) then room temperature (10 ml) (for 3 days) then carrageenan (1 ml) (for 6 hours),68404,room temperature (14 ml) (for 3 days),,room temperature (10 ml) (for 3 days),,carrageenan (1 ml) (for 6 hours), 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",eicosanoid amount,,RS:0000363,F344/NHsd,female,98 days to 56 days,9,,CMO:0001438,inflammatory exudate leukotriene B4 level,,inflammatory exudate LTB4 measurement,median,469,pg/ml,,,MMO:0000075,enzyme linked immunosorbent assay,subcutaneous interscapular cavity,0.0,,,,,room temperature (14 ml) (for 3 days) then room temperature (10 ml) (for 3 days) then carrageenan (1 ml) (for 6 hours),68407,room temperature (14 ml) (for 3 days),,room temperature (10 ml) (for 3 days),,carrageenan (1 ml) (for 6 hours), 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",eicosanoid amount,,RS:0000363,F344/NHsd,female,98 days to 56 days,8,,CMO:0001439,inflammatory exudate lipoxin A4 level,,inflammatory exudate LXA4 measurementasurement,median,41,pg/ml,,,MMO:0000075,enzyme linked immunosorbent assay,subcutaneous interscapular cavity,0.0,,,,,room temperature (14 ml) (for 3 days) then room temperature (10 ml) (for 3 days) then carrageenan (1 ml) (for 6 hours),68409,room temperature (14 ml) (for 3 days),,room temperature (10 ml) (for 3 days),,carrageenan (1 ml) (for 6 hours), 332,"Laragione T, et al., J Immunol. 2007 Feb 15;178(4):2344-51.",eicosanoid amount,,RS:0000363,F344/NHsd,female,98 days to 56 days,9,,CMO:0001441,inflammatory exudate leukotriene B4 level to lipoxin A4 level ratio,,inflammatory exudate LTB4 to LXA4 ratio,,11.4,,,,MMO:0000075,enzyme linked immunosorbent assay,subcutaneous interscapular cavity,0.0,,,,,room temperature (14 ml) (for 3 days) then room temperature (10 ml) (for 3 days) then carrageenan (1 ml) (for 6 hours),68411,room temperature (14 ml) (for 3 days),,room temperature (10 ml) (for 3 days),,carrageenan (1 ml) (for 6 hours), 233,"Sebkhi A, et al., Hypertension 1999 Apr;33(4):949-53.",heart left ventricle mass,,RS:0000363,F344/NHsd,not specified,84 days,23,,CMO:0000530,heart left ventricle weight to body weight ratio,,,,2.1,mg/g,0.0209,0.1,MMO:0000005,post excision weight measurement,,,,,,,control condition,12179,control condition,,,,, 233,"Sebkhi A, et al., Hypertension 1999 Apr;33(4):949-53.",heart left ventricle mass,,RS:0000363,F344/NHsd,not specified,84 days,23,,CMO:0000071,heart left ventricle wet weight,,,,0.5462,g,0.0084,0.0402,MMO:0000005,post excision weight measurement,,,,,,,control condition,12193,control condition,,,,, 233,"Sebkhi A, et al., Hypertension 1999 Apr;33(4):949-53.",heart mass,,RS:0000363,F344/NHsd,not specified,84 days,23,,CMO:0000069,heart wet weight,,,,0.7212,g,0.0112,0.0538,MMO:0000005,post excision weight measurement,,,,,,,control condition,12159,control condition,,,,, 233,"Sebkhi A, et al., Hypertension 1999 Apr;33(4):949-53.",body mass,,RS:0000363,F344/NHsd,not specified,84 days,23,,CMO:0000012,body weight,,,,262.8,g,4.4831,21.5,MMO:0000016,body weighing method,,0.0,,,,,control condition,12133,control condition,,,,, 233,"Sebkhi A, et al., Hypertension 1999 Apr;33(4):949-53.",heart right ventricle mass,,RS:0000363,F344/NHsd,not specified,84 days,23,,CMO:0000072,heart right ventricle wet weight,,,,0.1366,g,0.0032,0.0154,MMO:0000005,post excision weight measurement,,,,,,,control condition,12162,control condition,,,,, 233,"Sebkhi A, et al., Hypertension 1999 Apr;33(4):949-53.",arterial blood pressure trait,,RS:0000363,F344/NHsd,not specified,84 days,9,,CMO:0000009,mean arterial blood pressure,,,,86,mmHg,2.0,6.0,MMO:0000011,vascular indwelling catheter method,carotid artery,0.0,"pressure transducer (Cobe Laboratories Inc), MacLab 4 integrated data acquisition system (AD Instruments)",,,,control condition,12163,control condition,,,,, 252,"Baum AE, et al., Endocrinology 2004 Oct 28;.",blood thyroid-stimulating hormone amount,,RS:0000363,F344/NHsd,male,0 days to 70 days,16,,CMO:0001248,serum thyroid stimulating hormone level,,serum tsh,,2.23,ng/ml,0.155,0.62,MMO:0000073,radioimmunoassay,,0.0,,,,,control condition,12405,control condition,,,,, 252,"Baum AE, et al., Endocrinology 2004 Oct 28;.",blood thyroid-stimulating hormone amount,,RS:0000363,F344/NHsd,female,0 days to 70 days,15,,CMO:0001248,serum thyroid stimulating hormone level,,serum tsh,,1.13,ng/ml,0.0181,0.07,MMO:0000073,radioimmunoassay,,0.0,,,,,control condition,67896,control condition,,,,, 529,PhysGen General data,body length,,RS:0000363,F344/NHsd,male,84 days to 70 days,10,,CMO:0000078,"body length, nose to tail",,,,27.55,cm,2.7873,8.8143,MMO:0000211,in vivo ruler method,,,,,,,controlled sodium content diet (4 %) (for 14 days),63680,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,body length,,RS:0000363,F344/NHsd,female,84 days to 70 days,10,,CMO:0000078,"body length, nose to tail",,,,23.85,cm,2.5277,7.9932,MMO:0000211,in vivo ruler method,,,,,,,controlled sodium content diet (4 %) (for 14 days),63689,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,heart left ventricle mass,,RS:0000363,F344/NHsd,male,84 days to 70 days,10,,CMO:0000071,heart left ventricle wet weight,,,,0.421,g,0.012,0.038,MMO:0000157,digital scale post excision weight measurement,,,,,,,controlled sodium content diet (4 %) (for 14 days),63752,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,heart left ventricle mass,,RS:0000363,F344/NHsd,female,84 days to 70 days,10,,CMO:0000071,heart left ventricle wet weight,,,,0.3043,g,0.0062,0.0196,MMO:0000157,digital scale post excision weight measurement,,,,,,,controlled sodium content diet (4 %) (for 14 days),63761,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,heart right ventricle mass,,RS:0000363,F344/NHsd,male,84 days to 70 days,10,,CMO:0000072,heart right ventricle wet weight,,,,0.1135,g,0.0045,0.0141,MMO:0000157,digital scale post excision weight measurement,,,,,,,controlled sodium content diet (4 %) (for 14 days),63290,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,heart right ventricle mass,,RS:0000363,F344/NHsd,female,84 days to 70 days,10,,CMO:0000072,heart right ventricle wet weight,,,,0.0841,g,0.003,0.0094,MMO:0000157,digital scale post excision weight measurement,,,,,,,controlled sodium content diet (4 %) (for 14 days),63299,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,kidney mass,,RS:0000363,F344/NHsd,male,84 days to 70 days,10,,CMO:0000083,left kidney wet weight,,,,0.7448,g,0.027,0.0855,MMO:0000157,digital scale post excision weight measurement,,,,,,,controlled sodium content diet (4 %) (for 14 days),63362,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,kidney mass,,RS:0000363,F344/NHsd,female,84 days to 70 days,10,,CMO:0000083,left kidney wet weight,,,,0.5529,g,0.0155,0.0491,MMO:0000157,digital scale post excision weight measurement,,,,,,,controlled sodium content diet (4 %) (for 14 days),63371,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,heart mass,,RS:0000363,F344/NHsd,male,84 days to 70 days,10,,CMO:0000069,heart wet weight,,,,0.6284,g,0.0203,0.0641,MMO:0000157,digital scale post excision weight measurement,,,,,,,controlled sodium content diet (4 %) (for 14 days),63434,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,heart mass,,RS:0000363,F344/NHsd,female,84 days to 70 days,10,,CMO:0000069,heart wet weight,,,,0.4597,g,0.0098,0.031,MMO:0000157,digital scale post excision weight measurement,,,,,,,controlled sodium content diet (4 %) (for 14 days),63443,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,body length,,RS:0000363,F344/NHsd,male,84 days to 70 days,10,,CMO:0000079,"body length, nose to rump",,,,29.95,cm,2.6619,8.4177,MMO:0000211,in vivo ruler method,,,,,,,controlled sodium content diet (4 %) (for 14 days),63526,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,body length,,RS:0000363,F344/NHsd,female,84 days to 70 days,10,,CMO:0000079,"body length, nose to rump",,,,26.9,cm,2.3152,7.3212,MMO:0000211,in vivo ruler method,,,,,,,controlled sodium content diet (4 %) (for 14 days),63535,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,body mass,,RS:0000363,F344/NHsd,male,84 days to 70 days,10,,CMO:0000012,body weight,,,,198.7,g,4.4946,14.2131,MMO:0000017,whole body digital scale,,,,,,,controlled sodium content diet (4 %) (for 14 days),63608,controlled sodium content diet (4 %) (for 14 days),,,,, 529,PhysGen General data,body mass,,RS:0000363,F344/NHsd,female,84 days to 70 days,10,,CMO:0000012,body weight,,,,128.5,g,2.1252,6.7206,MMO:0000017,whole body digital scale,,,,,,,controlled sodium content diet (4 %) (for 14 days),63617,controlled sodium content diet (4 %) (for 14 days),,,,, 527,PhysGen Biochemistry data,eosinophil quantity,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000033,blood eosinophil count,,,,0.0286,x 1000 cells/ul,0.0168,0.0445,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62227,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,eosinophil quantity,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000033,blood eosinophil count,,,,0.0275,x 1000 cells/ul,0.0103,0.0206,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62236,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood hemoglobin amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000290,mean corpuscular hemoglobin,,,,17.8714,pg,0.0714,0.189,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60485,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood hemoglobin amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000290,mean corpuscular hemoglobin,,,,18.3,pg,0.0707,0.1414,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60494,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,erythrocyte quantity,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000025,red blood cell count,,,,8.1771,x 10E6 cells/ul,0.1722,0.4555,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60567,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,erythrocyte quantity,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000025,red blood cell count,,,,8.245,x 10E6 cells/ul,0.5423,1.0846,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60576,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood chloride amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000489,serum chloride level,,,,101.8571,mmol/l,1.1004,2.9114,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62309,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood chloride amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000489,serum chloride level,,,,109.75,mmol/l,3.66,7.3201,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62318,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood cholesterol amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000363,serum total cholesterol level,,,,39.1429,mg/dl,1.5649,4.1404,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62381,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,erythrocyte quantity,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000037,hematocrit,,,,45.3,%,1.1688,3.0925,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60649,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,erythrocyte quantity,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000037,hematocrit,,,,46.375,%,2.8028,5.6056,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60658,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood cholesterol amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000363,serum total cholesterol level,,,,60,mg/dl,7.4274,14.8549,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62390,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood glucose amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000543,serum glucose level,,,,214.4286,mg/dl,16.3414,43.2352,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62473,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood glucose amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000543,serum glucose level,,,,149.25,mg/dl,20.0141,40.0281,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62482,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,erythrocyte size trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000038,mean corpuscular volume,,,,55.3571,fl,0.3007,0.7955,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60761,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,erythrocyte size trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000038,mean corpuscular volume,,,,56.325,fl,0.4308,0.8617,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60770,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,neutrophil quantity,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000030,blood neutrophil count,,,,0.6914,x 1000 cells/ul,0.1369,0.3623,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60853,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,neutrophil quantity,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000030,blood neutrophil count,,,,0.785,x 1000 cells/ul,0.3589,0.7179,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60862,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood globulin amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0002399,serum globulin level,,"replaced obsolete serum globulin level term, 1/19/2016",,1.9714,g/dl,0.068,0.1799,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60935,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood globulin amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0002399,serum globulin level,,"replaced obsolete serum globulin level term, 1/19/2016",,1.725,g/dl,0.0854,0.1708,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60944,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood creatinine amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000537,plasma creatinine level,,,,0.3143,mg/dl,0.0261,0.069,MMO:0000354,automated plasma creatinine analysis,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (between 16 and 1 hours),61017,controlled sodium content diet (4 %) (for 14 days),,fasting (between 16 and 1 hours),,, 527,PhysGen Biochemistry data,blood creatinine amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000537,plasma creatinine level,,,,0.55,mg/dl,0.0866,0.1732,MMO:0000354,automated plasma creatinine analysis,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (between 16 and 1 hours),61026,controlled sodium content diet (4 %) (for 14 days),,fasting (between 16 and 1 hours),,, 527,PhysGen Biochemistry data,ion homeostasis trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000066,plasma anion gap,,,,24.2857,mmol/l,1.1895,3.1472,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61089,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,ion homeostasis trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000066,plasma anion gap,,,,28,mmol/l,1.9579,3.9158,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61098,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood hemoglobin amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,32.2857,g/dl,0.1654,0.4375,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61161,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood hemoglobin amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000291,mean corpuscular hemoglobin concentration,,,,32.475,g/dl,0.2394,0.4787,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61170,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood total protein amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000661,serum total protein level,,,,5.6286,g/dl,0.0865,0.2289,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61243,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood total protein amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000661,serum total protein level,,,,5,g/dl,0.2483,0.4967,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61252,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood potassium amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000495,serum potassium level,,,,3.8,mmol/l,0.1618,0.4282,MMO:0000039,flame atomic emission spectrometry,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61315,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood potassium amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000495,serum potassium level,,,,4.8,mmol/l,0.8266,1.6533,MMO:0000039,flame atomic emission spectrometry,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61324,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,leukocyte quantity,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000365,total white blood cell count,,,,4.5286,x 1000 cells/ul,0.6865,1.8163,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61387,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,leukocyte quantity,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000365,total white blood cell count,,,,4.175,x 1000 cells/ul,0.5977,1.1955,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61396,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood alanine transaminase amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000575,serum alanine aminotransferase activity level,,,,73.2857,U/l,14.1383,37.4064,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61459,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood alanine transaminase amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000575,serum alanine aminotransferase activity level,,,,92,U/l,30.5641,61.1283,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61468,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood phosphate amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000542,serum phosphate level,,,,8.4429,mg/dl,0.3169,0.8384,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61551,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood phosphate amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000542,serum phosphate level,,,,8.825,mg/dl,1.1514,2.3027,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61560,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood bicarbonate amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000488,serum bicarbonate level,,,,20.4286,mmol/l,0.7514,1.9881,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61623,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood bicarbonate amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000488,serum bicarbonate level,,,,14.5,mmol/l,1.5,3.0,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61632,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood urea nitrogen amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000587,serum urea nitrogen level,,,,22.4286,mg/dl,1.2884,3.4087,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60167,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood urea nitrogen amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000587,serum urea nitrogen level,,,,32.25,mg/dl,4.6075,9.215,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60176,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood calcium amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000503,serum calcium level,,,,9.6429,mg/dl,0.1152,0.3047,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60239,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood calcium amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000503,serum calcium level,,,,8.55,mg/dl,0.1041,0.2082,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60248,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,monocyte quantity,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000032,blood monocyte count,,,,0.0457,x 1000 cells/ul,0.0229,0.0605,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61695,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,monocyte quantity,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000032,blood monocyte count,,,,0.0075,x 1000 cells/ul,0.0075,0.015,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61704,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood hemoglobin amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000026,blood hemoglobin level,,,,14.6143,g/dl,0.3341,0.884,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60321,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood hemoglobin amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000026,blood hemoglobin level,,,,15.05,g/dl,0.9971,1.9942,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60330,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood sodium amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000500,serum sodium level,,,,142.5714,mmol/l,1.6741,4.4293,MMO:0000039,flame atomic emission spectrometry,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61797,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood sodium amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000500,serum sodium level,,,,147.25,mmol/l,2.9545,5.909,MMO:0000039,flame atomic emission spectrometry,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61806,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood alkaline phosphatase amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000577,serum alkaline phosphatase activity level,,,,221.1429,U/l,7.6794,20.3177,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60413,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood alkaline phosphatase amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000577,serum alkaline phosphatase activity level,,,,142.75,U/l,7.5429,15.0859,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),60422,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood albumin amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000550,serum albumin level,,,,3.6571,g/dl,0.0649,0.1718,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61919,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood albumin amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000550,serum albumin level,,,,3.275,g/dl,0.1652,0.3304,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61928,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood aspartate transaminase amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000581,serum aspartate aminotransferase activity level,,,,186,U/l,21.3876,56.5862,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),61991,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood aspartate transaminase amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000581,serum aspartate aminotransferase activity level,,,,224,U/l,63.8462,127.6923,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62000,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,lymphocyte quantity,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000031,blood lymphocyte count,,,,3.7671,x 1000 cells/ul,0.6224,1.6467,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62073,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,lymphocyte quantity,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000031,blood lymphocyte count,,,,3.355,x 1000 cells/ul,0.6515,1.303,MMO:0000146,automated blood cell counting method,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62082,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood bilirubin amount,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000376,serum total bilirubin level,,,,0.0714,mg/dl,0.0101,0.0267,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62145,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 527,PhysGen Biochemistry data,blood bilirubin amount,,RS:0000363,F344/NHsd,female,84 days to 70 days,4,,CMO:0000376,serum total bilirubin level,,,,0.1125,mg/dl,0.0315,0.0629,MMO:0000169,standard blood chemistry panel,,,,,,,controlled sodium content diet (4 %) (for 14 days) then fasting (for 16 hours),62154,controlled sodium content diet (4 %) (for 14 days),,fasting (for 16 hours),,, 528,PhysGen Vascular data,vasodilation trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,42.4286,%,3.3228,8.7912,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),62612,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours) 528,PhysGen Vascular data,vasodilation trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,8,,CMO:0000731,acetylcholine-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel,,,,54.125,%,6.8229,19.2979,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),62621,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours) 528,PhysGen Vascular data,vasoconstriction trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0112,umol/l,0.0035,0.0104,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62757,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),, 528,PhysGen Vascular data,vasoconstriction trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,9,,CMO:0000721,concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50),,,,0.0105,umol/l,0.0041,0.0122,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),62766,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),, 528,PhysGen Vascular data,vasodilation trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-6.6054,,0.1846,0.4883,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),62835,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours) 528,PhysGen Vascular data,vasodilation trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,8,,CMO:0000725,logarithm of the concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (Log EC50),,,,-6.8444,,0.1215,0.3437,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),62844,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours) 528,PhysGen Vascular data,body mass,,RS:0000363,F344/NHsd,male,84 days to 70 days,10,,CMO:0000012,body weight,,,,198.7,g,4.4946,14.2131,MMO:0000017,whole body digital scale,,,,,,,controlled sodium content diet (4 %) (for 14 days),62923,controlled sodium content diet (4 %) (for 14 days),,,,, 528,PhysGen Vascular data,body mass,,RS:0000363,F344/NHsd,female,84 days to 70 days,10,,CMO:0000012,body weight,,,,128.3,g,2.1398,6.7667,MMO:0000017,whole body digital scale,,,,,,,controlled sodium content diet (4 %) (for 14 days),62932,controlled sodium content diet (4 %) (for 14 days),,,,, 528,PhysGen Vascular data,vasodilation trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,7,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,5.3924,E-7mole,3.6091,9.5488,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),63012,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours) 528,PhysGen Vascular data,vasodilation trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,8,,CMO:0000724,concentration of acetylcholine at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50),,,,1.8975,E-7mole,0.5563,1.5735,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (1 umol/l) (for 0.2 hours) then acetylcholine (0-30 umol/l) and drug dose time series (for 1 hours),63021,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (1 umol/l) (for 0.2 hours),,acetylcholine (0-30 umol/l) ,drug dose time series (for 1 hours) 528,PhysGen Vascular data,vasoconstriction trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,9,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-8.0918,,0.1208,0.3625,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),63080,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),, 528,PhysGen Vascular data,vasoconstriction trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,9,,CMO:0000722,logarithm of the concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (Log EC50),,EC50 value is moles/liter,,-8.2039,,0.1502,0.4505,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then phenylephrine (0-300 umol/l) and drug dose time series (for 1.2 hours),63089,controlled sodium content diet (4 %) (for 14 days),,phenylephrine (0-300 umol/l) ,drug dose time series (for 1.2 hours),, 528,PhysGen Vascular data,vasoconstriction trait,,RS:0000363,F344/NHsd,male,84 days to 70 days,8,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,0.9525,g/mg,0.1128,0.3191,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),63149,controlled sodium content diet (4 %) (for 14 days),,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),, 528,PhysGen Vascular data,vasoconstriction trait,,RS:0000363,F344/NHsd,female,84 days to 70 days,9,,CMO:0000728,maximum contractile force per wet weight of aorta,,,,1.0011,g/mg,0.0728,0.2185,MMO:0000208,wire myography using a Digi-Med tissue force analysis system with force transducer,,,,,,,controlled sodium content diet (4 %) (for 14 days) then potassium ion (80 mmol/l) (for 0.2 hours) and phenylephrine (10 umol/l) (for 0.2 hours),63158,controlled sodium content diet (4 %) (for 14 days),,potassium ion (80 mmol/l) (for 0.2 hours),phenylephrine (10 umol/l) (for 0.2 hours),, 912,"De Miglio MR, et al., Cancer Res 1999 Sep 15;59(18):4651-7.",liver integrity trait,,RS:0000363,F344/NHsd,not specified,0 days,9,,CMO:0002600,hepatocellular carcinoma tumor number,,,,3.5,,0.23,0.69,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,N-nitrosodiethylamine,490,days,N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 mg/kg) (for 490 days) then partial hepatectomy,68391,N-nitrosodiethylamine (150 mg/kg) ,,2-acetamidofluorene (0.02 mg/kg) (for 490 days),,partial hepatectomy, 912,"De Miglio MR, et al., Cancer Res 1999 Sep 15;59(18):4651-7.",liver integrity trait,,RS:0000363,F344/NHsd,not specified,0 days,12,,CMO:0001068,liver tumorous lesion number,,CMO:0001068,,126820,,9698.0,33594.8575,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,N-nitrosodiethylamine,224,days,N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 210 days) then partial hepatectomy,68349,N-nitrosodiethylamine (150 mg/kg) ,,2-acetamidofluorene (0.02 %) (for 210 days),,partial hepatectomy, 912,"De Miglio MR, et al., Cancer Res 1999 Sep 15;59(18):4651-7.",liver integrity trait,,RS:0000363,F344/NHsd,not specified,0 days,12,,CMO:0001078,volume of individual liver tumorous lesion,,,,2.95,cm3 x 10000,0.35,312.9816,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,N-nitrosodiethylamine,224,days,N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 210 days) then partial hepatectomy,68351,N-nitrosodiethylamine (150 mg/kg) ,,2-acetamidofluorene (0.02 %) (for 210 days),,partial hepatectomy, 912,"De Miglio MR, et al., Cancer Res 1999 Sep 15;59(18):4651-7.",liver integrity trait,,RS:0000363,F344/NHsd,not specified,0 days,12,,CMO:0001081,volume of liver occupied by tumorous lesions as percentage of total liver volume,,,,84.18,%,3.64,12.6093,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,N-nitrosodiethylamine,224,days,N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 210 days) then partial hepatectomy,68353,N-nitrosodiethylamine (150 mg/kg) ,,2-acetamidofluorene (0.02 %) (for 210 days),,partial hepatectomy, 912,"De Miglio MR, et al., Cancer Res 1999 Sep 15;59(18):4651-7.",liver integrity trait,,RS:0000363,F344/NHsd,not specified,0 days,9,,CMO:0002602,percentage of study population developing hepatocellular carcinoma during a period of time,,CMO:0001068,,89,%,,,MMO:0000344,necropsy,,0.0,,N-nitrosodiethylamine,490,days,N-nitrosodiethylamine (150 mg/kg) then 2-acetamidofluorene (0.02 %) (for 490 days) then partial hepatectomy,96757,N-nitrosodiethylamine (150 mg/kg) ,,2-acetamidofluorene (0.02 %) (for 490 days),,partial hepatectomy, 970,"Potenza MN, et al., Biol Psychiatry 2004 Mar 15;55(6):634-41.",blood corticosterone amount,,RS:0000363,F344/NHsd,male,59 days to 49 days,9,,CMO:0001173,plasma corticosterone level,,,,95.9,ng/ml,16.73,50.19,MMO:0000073,radioimmunoassay,,0.0,,,,,controlled exposure to ambient light (for 12 hours),68640,controlled exposure to ambient light (for 12 hours),,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",stationary movement trait,,RS:0000363,F344/NHsd,female,88 days to 77 days,18,,CMO:0001752,number of rearing movements in an experimental apparatus,,in 10min,,25.8,,2.1213,9.0,MMO:0000559,defensive burying test,,600.0,defensive burying,,,,control condition,69438,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",grooming behavior trait,,RS:0000363,F344/NHsd,female,88 days to 77 days,22,,CMO:0001749,duration of grooming in an experimental apparatus,,in 10min,,178.5,s,18.8256,88.3,MMO:0000258,open field apparatus method,,600.0,,,,,control condition,68651,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",grooming behavior trait,,RS:0000363,F344/NHsd,male,88 days to 77 days,28,,CMO:0001749,duration of grooming in an experimental apparatus,,in 10min,,151.9,s,12.6429,66.9,MMO:0000258,open field apparatus method,,600.0,,,,,control condition,68653,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",stationary movement trait,,RS:0000363,F344/NHsd,male,88 days to 77 days,20,,CMO:0001752,number of rearing movements in an experimental apparatus,,in 10min,,21.7,,2.2808,10.2,MMO:0000559,defensive burying test,,600.0,defensive burying apparatus,,,,control condition,75693,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",locomotor behavior trait,,RS:0000363,F344/NHsd,female,88 days to 77 days,22,,CMO:0000960,number of entries into a discrete space in an experimental apparatus,,inner line crossings; unprompted,,13.9,,1.8548,8.7,MMO:0000258,open field apparatus method,,600.0,,,,,control condition,75705,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",grooming behavior trait,,RS:0000363,F344/NHsd,female,88 days to 77 days,18,,CMO:0001749,duration of grooming in an experimental apparatus,,in 10min,,152,s,22.816,96.8,MMO:0000559,defensive burying test,,600.0,defensive burying apparatus,,,,control condition,75699,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",grooming behavior trait,,RS:0000363,F344/NHsd,male,88 days to 77 days,20,,CMO:0001749,duration of grooming in an experimental apparatus,,in 10min,,163.8,s,20.706,92.6,MMO:0000559,defensive burying test,,600.0,defensive burying apparatus,,,,control condition,75701,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",stationary movement trait,,RS:0000363,F344/NHsd,female,88 days to 77 days,22,,CMO:0001752,number of rearing movements in an experimental apparatus,,in 10min,,28.8,,2.4731,11.6,MMO:0000258,open field apparatus method,,600.0,,,,,control condition,75695,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",stationary movement trait,,RS:0000363,F344/NHsd,male,88 days to 77 days,28,,CMO:0001752,number of rearing movements in an experimental apparatus,,in 10min,,25.9,,2.4568,13.0,MMO:0000258,open field apparatus method,,600.0,,,,,control condition,75697,control condition,,,,, 972,"Baum AE, et al., Behav Brain Res. 2006 Feb 17;.",locomotor behavior trait,,RS:0000363,F344/NHsd,male,88 days to 77 days,28,,CMO:0000960,number of entries into a discrete space in an experimental apparatus,,inner line crossings; unprompted,,10.2,,1.3229,7.0,MMO:0000258,open field apparatus method,,600.0,,,,,control condition,75703,control condition,,,,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001622,percentage of study population developing pituitary gland hyperplastic lesions during a period of time,,,,0,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69912,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001618,percentage of study population developing pituitary tumors that replace a portion of the gland during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69913,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001617,percentage of study population developing pituitary tumors that replace the entire gland during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69914,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,,, 1240,"Pandey J, et al., Carcinogenesis 2004 May 27;.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,not specified,91 days,6,,CMO:0001619,percentage of study population developing pituitary tumors that invade the glandular capsule during a period of time,,,,50,%,,,MMO:0000111,ex vivo light microscopy,,0.0,xco:0000295,surgery implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),69915,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",liver mass,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0000158,liver wet weight,,,,10.9,g,0.4,1.2,MMO:0000005,post excision weight measurement,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84699,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",body mass,,RS:0000363,F344/NHsd,male,267 days to 123 days,8,,CMO:0000012,body weight,,,,379.3,g,9.2,26.0215,MMO:0000016,body weighing method,,0.0,,,,,control condition,84700,control condition,,,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",body mass,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0000012,body weight,,,,424.8,g,14.5,43.5,MMO:0000016,body weighing method,,0.0,,,,,control condition,84701,control condition,,,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",body mass,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000012,body weight,,,,429.1,g,30.0,67.082,MMO:0000016,body weighing method,,0.0,,,,,control condition,84702,control condition,,,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",body mass,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0000012,body weight,,,,375.7,g,8.1,24.3,MMO:0000016,body weighing method,,0.0,,,,,fasting (for 16 hours),84703,fasting (for 16 hours),,,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",body mass,,RS:0000363,F344/NHsd,male,267 days to 123 days,8,,CMO:0000012,body weight,,,,371.3,g,8.3,23.4759,MMO:0000016,body weighing method,,0.0,,,,,fasting (for 16 hours),84704,fasting (for 16 hours),,,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",body mass,,RS:0000363,F344/NHsd,male,264 days to 132 days,5,,CMO:0000012,body weight,,,,381.2,g,9.4,21.019,MMO:0000016,body weighing method,,0.0,,,,,control condition,84708,control condition,,,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood alanine transaminase amount,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0000575,serum alanine aminotransferase activity level,,,,55,U/l,3.4,10.2,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84711,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood alanine transaminase amount,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0000575,serum alanine aminotransferase activity level,,,,54.5,U/l,6.4,19.2,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84713,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood alanine transaminase amount,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000575,serum alanine aminotransferase activity level,,,,51,U/l,8.0,17.8885,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84714,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood aspartate transaminase amount,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000581,serum aspartate aminotransferase activity level,,,,194.6,U/l,29.1,65.0696,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84718,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood alkaline phosphatase amount,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0000577,serum alkaline phosphatase activity level,,,,98.8,U/l,5.3,15.9,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84719,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood alkaline phosphatase amount,,RS:0000363,F344/NHsd,male,267 days to 123 days,7,,CMO:0000577,serum alkaline phosphatase activity level,,,,85.3,U/l,9.9,26.1929,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84720,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood alkaline phosphatase amount,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0000577,serum alkaline phosphatase activity level,,,,71.6,U/l,9.4,28.2,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84721,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood alkaline phosphatase amount,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000577,serum alkaline phosphatase activity level,,,,48.2,U/l,5.8,12.9692,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84722,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood gamma-glutamyltransferase amount,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0002241,serum gamma-glutamyltransferase activity level,,,,1.2,U/l,0.1,0.3,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84723,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood gamma-glutamyltransferase amount,,RS:0000363,F344/NHsd,male,267 days to 123 days,8,,CMO:0002241,serum gamma-glutamyltransferase activity level,,,,1.6,U/l,1.0,2.8284,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84724,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood gamma-glutamyltransferase amount,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0002241,serum gamma-glutamyltransferase activity level,,,,2.1,U/l,0.9,2.7,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84725,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood gamma-glutamyltransferase amount,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0002241,serum gamma-glutamyltransferase activity level,,,,1.2,U/l,0.2,0.4472,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84726,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood total protein amount,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0000661,serum total protein level,,,,623,g/dl,8.0,24.0,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84727,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood total protein amount,,RS:0000363,F344/NHsd,male,267 days to 123 days,8,,CMO:0000661,serum total protein level,,,,579,g/dl,14.0,39.598,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84728,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood total protein amount,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0000661,serum total protein level,,,,548,g/dl,51.0,153.0,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84729,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood albumin amount,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0000550,serum albumin level,,,,136,g/dl,3.0,9.0,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84731,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood albumin amount,,RS:0000363,F344/NHsd,male,267 days to 123 days,8,,CMO:0000550,serum albumin level,,,,126,g/dl,4.0,11.3137,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84732,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood albumin amount,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0000550,serum albumin level,,,,104,g/dl,10.0,30.0,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84733,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood albumin amount,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000550,serum albumin level,,,,108,g/dl,9.0,20.1246,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84734,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood bilirubin amount,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0000376,serum total bilirubin level,,,,5.8466,mg/dl,1.1693,3.508,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84735,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood bilirubin amount,,RS:0000363,F344/NHsd,male,267 days to 123 days,8,,CMO:0000376,serum total bilirubin level,,,,7.60058,mg/dl,1.1693,3.3073,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84736,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood bilirubin amount,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0000376,serum total bilirubin level,,,,14.6165,mg/dl,1.1693,3.508,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84737,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood bilirubin amount,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000376,serum total bilirubin level,,,,9.35456,mg/dl,1.1693,2.6147,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84738,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood creatinine amount,,RS:0000363,F344/NHsd,male,264 days to 132 days,6,,CMO:0000057,serum creatinine level,,,,0.37855,mg/dl,0.0045,0.0111,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84739,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood creatinine amount,,RS:0000363,F344/NHsd,male,267 days to 123 days,6,,CMO:0000057,serum creatinine level,,,,0.46556,mg/dl,0.0249,0.0609,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84740,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood creatinine amount,,RS:0000363,F344/NHsd,male,945 days to 579 days,7,,CMO:0000057,serum creatinine level,,,,0.3729,mg/dl,0.0509,0.1345,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84741,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood creatinine amount,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000057,serum creatinine level,,,,0.73902,mg/dl,0.0904,0.2021,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84742,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood alanine transaminase amount,,RS:0000363,F344/NHsd,male,267 days to 123 days,8,,CMO:0000575,serum alanine aminotransferase activity level,,,,109.3,U/l,14.3,40.4465,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84712,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood aspartate transaminase amount,,RS:0000363,F344/NHsd,male,264 days to 132 days,9,,CMO:0000581,serum aspartate aminotransferase activity level,,,,112.4,U/l,11.3,33.9,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84715,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood aspartate transaminase amount,,RS:0000363,F344/NHsd,male,267 days to 123 days,7,,CMO:0000581,serum aspartate aminotransferase activity level,,,,349.6,U/l,34.3,90.7493,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84716,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood aspartate transaminase amount,,RS:0000363,F344/NHsd,male,945 days to 579 days,6,,CMO:0000581,serum aspartate aminotransferase activity level,,,,120.8,U/l,12.9,31.5984,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84717,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",blood total protein amount,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000661,serum total protein level,,,,592,g/dl,13.0,29.0689,MMO:0000160,unspecified method,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84730,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",body mass,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0000012,body weight,,,,419.9,g,12.2,36.6,MMO:0000016,body weighing method,,0.0,,,,,fasting (for 16 hours),84705,fasting (for 16 hours),,,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",body mass,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000012,body weight,,,,415.7,g,28.9,64.6224,MMO:0000016,body weighing method,,0.0,,,,,fasting (for 16 hours),84706,fasting (for 16 hours),,,,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",liver mass,,RS:0000363,F344/NHsd,male,882 days to 714 days,5,,CMO:0000158,liver wet weight,,,,11.8,g,0.9,2.0125,MMO:0000005,post excision weight measurement,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84707,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",liver mass,,RS:0000363,F344/NHsd,male,267 days to 123 days,8,,CMO:0000158,liver wet weight,,,,10,g,0.4,1.1314,MMO:0000005,post excision weight measurement,,0.0,,,,,fasting (for 16 hours) then acetaminophen (800 mg/kg) (for 4 hours),84709,fasting (for 16 hours),,acetaminophen (800 mg/kg) (for 4 hours),,, 1599,"Mach J, et al., J Gerontol A Biol Sci Med Sci. 2013 Jul 17.",liver mass,,RS:0000363,F344/NHsd,male,945 days to 579 days,9,,CMO:0000158,liver wet weight,,,,11.7,g,0.4,1.2,MMO:0000005,post excision weight measurement,,0.0,,,,,fasting (for 16 hours) then sodium chloride solution (for 4 hours),84710,fasting (for 16 hours),,sodium chloride solution (for 4 hours),,, 1601,"McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23.",blood alanine transaminase amount,,RS:0000363,F344/NHsd,not specified,84 days to 56 days,4,,CMO:0000575,serum alanine aminotransferase activity level,,,,35,U/l,11.0,22.0,MMO:0000173,spectrophotometry,,0.0,,,,,fasting (between 12 and 15 hours) then vehicle control condition (for 1 days),84754,fasting (between 12 and 15 hours),,vehicle control condition (for 1 days),,, 1601,"McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23.",blood alanine transaminase amount,,RS:0000363,F344/NHsd,not specified,84 days to 56 days,4,,CMO:0000575,serum alanine aminotransferase activity level,,,,39,U/l,4.0,8.0,MMO:0000173,spectrophotometry,,0.0,,,,,fasting (between 12 and 15 hours) then acetaminophen (1 g/kg) (for 1 days),84755,fasting (between 12 and 15 hours),,acetaminophen (1 g/kg) (for 1 days),,, 1601,"McGill MR, et al., Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94. doi: 10.1016/j.taap.2012.08.015. Epub 2012 Aug 23.",blood alanine transaminase amount,,RS:0000363,F344/NHsd,not specified,84 days to 56 days,4,,CMO:0000575,serum alanine aminotransferase activity level,,,,101,U/l,7.0,14.0,MMO:0000173,spectrophotometry,,0.0,,,,,fasting (between 12 and 15 hours) then acetaminophen (1.5 g/kg) (for 1 days),84756,fasting (between 12 and 15 hours),,acetaminophen (1.5 g/kg) (for 1 days),,, 1178,"de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84.",peripheral nervous system integrity trait,peripheral nervous system integrity trait,RS:0000363,F344/NHsd,male,200 days to 98 days,4,,CMO:0001522,percentage of study population developing experimental autoimmune neuritis during a period of time,,,,0,%,,,MMO:0000162,ex vivo visual assessment,,0.0,,,,,peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) ,84476,peripheral nerve myelin (2 mg) ,Freund's complete adjuvant (100 ul) ,,,, 1178,"de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84.",peripheral nervous system integrity trait,peripheral nervous system integrity trait,RS:0000363,F344/NHsd,male,200 days to 98 days,3,,CMO:0001522,percentage of study population developing experimental autoimmune neuritis during a period of time,,,,0,%,,,MMO:0000162,ex vivo visual assessment,,0.0,,,,,peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) ,84526,peripheral myelin protein 2 peptide 58-81 (100 ug) ,Freund's complete adjuvant (100 ul) ,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000363,F344/NHsd,male,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,20,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70148,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,, 1299,"Joe B, et al., Immunogenetics 2000 Sep;51(11):930-44.",joint integrity trait,,RS:0000363,F344/NHsd,female,126 days to 63 days,10,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,30,%,,,MMO:0000163,in vivo visual assessment,,3024000.0,,,,,type II collagen (2 mg/kg) and Freund's incomplete adjuvant (50 %) ,70149,type II collagen (2 mg/kg) ,Freund's incomplete adjuvant (50 %) ,,,, 1578,"Koller DL, et al., Mamm Genome 2005 Aug;16(8):578-86. Epub 2005 Sep 14.",lumbar vertebra mineral mass,,RS:0000363,F344/NHsd,female,182 days,16,,CMO:0001226,bone mineral density,,L3-L5,,0.2076,g/cm2,0.003,0.0121,MMO:0000363,dual-energy x-ray absorptiometry,lumbar vertebrae 3-5,0.0,,,,,control condition,76293,control condition,,,,, 1578,"Koller DL, et al., Mamm Genome 2005 Aug;16(8):578-86. Epub 2005 Sep 14.",femur mineral mass,,RS:0000363,F344/NHsd,female,182 days,16,,CMO:0001226,bone mineral density,,L3-L5,,0.2163,g/cm2,0.0023,0.0093,MMO:0000363,dual-energy x-ray absorptiometry,femur,0.0,,,,,control condition,76294,control condition,,,,, 1578,"Koller DL, et al., Mamm Genome 2005 Aug;16(8):578-86. Epub 2005 Sep 14.",lumbar vertebra mineral mass,,RS:0000363,F344/NHsd,female,182 days,16,,CMO:0001553,volumetric bone mineral density,,L3-L5,,684,mg/cm3,6.0,24.0,MMO:0000367,ex vivo peripheral quantitative computed tomography,lumbar vertebrae 3-5,0.0,,,,,control condition,76297,control condition,,,,, 1578,"Koller DL, et al., Mamm Genome 2005 Aug;16(8):578-86. Epub 2005 Sep 14.",femur mineral mass,,RS:0000363,F344/NHsd,female,182 days,16,,CMO:0001553,volumetric bone mineral density,,,,1314,mg/cm3,4.0,16.0,MMO:0000367,ex vivo peripheral quantitative computed tomography,diaphysis of femur,0.0,,,,,control condition,76298,control condition,,,,, 1578,"Koller DL, et al., Mamm Genome 2005 Aug;16(8):578-86. Epub 2005 Sep 14.",femur mineral mass,,RS:0000363,F344/NHsd,female,182 days,16,,CMO:0001553,volumetric bone mineral density,,,,666,mg/cm3,8.0,32.0,MMO:0000367,ex vivo peripheral quantitative computed tomography,distal epiphysis of femur,0.0,,,,,control condition,76299,control condition,,,,, 1838,"Pandey J and Wendell DL, Mamm Genome. 2006 Jan;17(1):49-57. Epub 2006 Jan 13.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,female,91 days,N/A,,CMO:0001757,lactotroph count to total pituicyte count ratio in prolactinoma,,,,99.1,%,,,MMO:0000538,ex vivo light microscopy with immunohistochemistry,,0.0,,subcutaneous implant,70,days,diethylstilbestrol (5 mg) (for 70 days) and surgical implantation (for 70 days),97077,diethylstilbestrol (5 mg) (for 70 days),surgical implantation (for 70 days),,,, 1838,"Pandey J and Wendell DL, Mamm Genome. 2006 Jan;17(1):49-57. Epub 2006 Jan 13.",pituitary gland integrity trait,,RS:0000363,F344/NHsd,female,91 days,N/A,,CMO:0001757,lactotroph count to total pituicyte count ratio in prolactinoma,,,,91.1,%,,,MMO:0000538,ex vivo light microscopy with immunohistochemistry,,0.0,,subcutaneous implant,70,days,control condition,97078,control condition,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,female,63 days,2,,CMO:0000012,body weight,,,,152,g,0.0,5.7,MMO:0000016,body weighing method,,0.0,,,,,control condition,106960,control condition,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,female,0 days to 98 days,2,,CMO:0000012,body weight,,,,224,g,0.0,9.2,MMO:0000016,body weighing method,,0.0,,,,,control condition,106961,control condition,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,female,0 days to 91 days,2,,CMO:0000012,body weight,,,,232,g,4.5255,6.4,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (1 ml) ,107013,0.9% sodium chloride solution (1 ml) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,male,0 days to 91 days,2,,CMO:0000012,body weight,,,,417,g,17.4655,24.7,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (1 ml) ,107014,0.9% sodium chloride solution (1 ml) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,female,0 days to 98 days,8,,CMO:0000012,body weight,,,,224,g,3.1113,8.8,MMO:0000016,body weighing method,,0.0,,,,,Azoxymethane (15 mg/kg) ,107004,Azoxymethane (15 mg/kg) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,male,0 days to 91 days,4,,CMO:0000012,body weight,,,,386,g,8.35,16.7,MMO:0000016,body weighing method,,0.0,,,,,Azoxymethane (15 mg/kg) ,107008,Azoxymethane (15 mg/kg) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",colorectal integrity trait,,RS:0000363,F344/NHsd,female,0 days to 217 days,4,,CMO:0001801,percentage of study population developing colorectal tumors during a period of time,,,,50,%,,,MMO:0000538,ex vivo light microscopy with immunohistochemistry,,0.0,,,,,Azoxymethane (15 mg/kg) ,107067,Azoxymethane (15 mg/kg) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",colorectal integrity trait,,RS:0000363,F344/NHsd,male,0 days to 217 days,4,,CMO:0001801,percentage of study population developing colorectal tumors during a period of time,,,,100,%,,,MMO:0000538,ex vivo light microscopy with immunohistochemistry,,0.0,,,,,Azoxymethane (15 mg/kg) ,107068,Azoxymethane (15 mg/kg) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,female,56 days,2,,CMO:0000012,body weight,,,,135,g,0.0,0.0,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (0.4 ml) ,106983,0.9% sodium chloride solution (0.4 ml) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,male,56 days,2,,CMO:0000012,body weight,,,,200,g,6.0104,8.5,MMO:0000016,body weighing method,,0.0,,,,,0.9% sodium chloride solution (0.4 ml) ,106984,0.9% sodium chloride solution (0.4 ml) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,female,63 days,8,,CMO:0000012,body weight,,,,161,g,2.3688,6.7,MMO:0000016,body weighing method,,0.0,,,,,Azoxymethane (15 mg/kg) ,106988,Azoxymethane (15 mg/kg) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,female,56 days,4,,CMO:0000012,body weight,,,,140,g,6.8,13.6,MMO:0000016,body weighing method,,0.0,,,,,Azoxymethane (15 mg/kg) ,106992,Azoxymethane (15 mg/kg) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,male,56 days,4,,CMO:0000012,body weight,,,,197,g,5.15,10.3,MMO:0000016,body weighing method,,0.0,,,,,Azoxymethane (15 mg/kg) ,106993,Azoxymethane (15 mg/kg) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",body mass,body weight,RS:0000363,F344/NHsd,female,0 days to 91 days,4,,CMO:0000012,body weight,,,,222,g,8.9,17.8,MMO:0000016,body weighing method,,0.0,,,,,Azoxymethane (15 mg/kg) ,107007,Azoxymethane (15 mg/kg) ,,,,, 3074,"Kobaek-Larsen M, etal., Comp Med. 2002 Feb;52(1):50-7.",colorectal integrity trait,,RS:0000363,F344/NHsd,female,0 days to 294 days,8,,CMO:0001801,percentage of study population developing colorectal tumors during a period of time,,,,25,%,,,MMO:0000538,ex vivo light microscopy with immunohistochemistry,,0.0,,,,,Azoxymethane (15 mg/kg) ,107018,Azoxymethane (15 mg/kg) ,,,,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",blood amount,,RS:0000363,F344/NHsd,male,95 days to 89 days,10,,CMO:0003663,volume of blood removed to total prehemorrhagic blood volume ratio,5.83 mL/100 g of body weight,volume of blood removed to total prehemorrhagic blood volume ratio (CMO:0003663),,57.8,%,0.4,1.2649,MMO:0000016,body weighing method,,0.0,,,,,arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours),109126,arterial catheter implantation (for 1 days),,controlled hemorrhage (for 0.4 hours),,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",erythrocyte quantity,"initial hematocrit, final hematocrit, change in hematocrit",RS:0000363,F344/NHsd,male,95 days to 89 days,10,,CMO:0000037,hematocrit,,,,42,%,2.1,6.6408,MMO:0000215,microhematocrit tube assay with visual assessment,,0.0,,,,,arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0 hours),107235,arterial catheter implantation (for 1 days),,controlled hemorrhage (for 0 hours),,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",erythrocyte quantity,"initial hematocrit, final hematocrit, change in hematocrit",RS:0000363,F344/NHsd,male,95 days to 89 days,10,,CMO:0000037,hematocrit,,,,33,%,0.7,2.2136,MMO:0000215,microhematocrit tube assay with visual assessment,,0.0,,,,,arterial catheter implantation (for 1 days) then controlled hemorrhage (for 0.4 hours),107252,arterial catheter implantation (for 1 days),,controlled hemorrhage (for 0.4 hours),,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",erythrocyte quantity,"initial hematocrit, final hematocrit, change in hematocrit",RS:0000363,F344/NHsd,male,95 days to 89 days,10,,CMO:0002538,absolute change in hematocrit,,,,9,%,2.3,7.2732,MMO:0000215,microhematocrit tube assay with visual assessment,,0.0,,,,,arterial catheter implantation (for 1 days) then controlled hemorrhage (between 0 and 0.4 hours),107268,arterial catheter implantation (for 1 days),,controlled hemorrhage (between 0 and 0.4 hours),,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",arterial blood pressure trait,Initial MAP,RS:0000363,F344/NHsd,male,95 days to 89 days,10,,CMO:0000009,mean arterial blood pressure,,,,128,mmHg,3.0,9.4868,MMO:0000013,vascular fluid filled catheter,,300.0,5-second intervals,,,,arterial catheter implantation (for 1 days),107332,arterial catheter implantation (for 1 days),,,,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",body mass,,RS:0000363,F344/NHsd,male,94 days to 88 days,10,,CMO:0000012,body weight,,,,283,g,8.0,25.2982,MMO:0000016,body weighing method,,0.0,,,,,control condition,107355,control condition,,,,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",drinking behavior trait,Water consumed (g) postsurgery per 100 g BW,RS:0000363,F344/NHsd,male,95 days to 89 days,10,,CMO:0002859,water intake drink rate to body weight ratio,,,,0.29,ml/d/kg,0.04,0.1265,MMO:0000619,drink intake measuring method,,,,arterial catheter implantation,1,days,arterial catheter implantation (for 1 days),107157,arterial catheter implantation (for 1 days),,,,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",body mass,,RS:0000363,F344/NHsd,male,95 days to 89 days,10,,CMO:0001400,maximum body weight loss to initial body weight ratio,,,,5.7,%,0.9,2.846,MMO:0000016,body weighing method,,0.0,,arterial catheter implantation,1,days,arterial catheter implantation (for 1 days),107176,arterial catheter implantation (for 1 days),,,,, 3077,"Klemcke HG, etal., Shock. 2008 Jun;29(6):748-53.",eating behavior trait,Food consumed (g) postsurgery per 100 g BW,RS:0000363,F344/NHsd,male,95 days to 89 days,10,,CMO:0002214,food intake weight to body weight ratio,,,,4.4,g/d/100g,0.4,1.2649,MMO:0000620,food intake measuring method,,0.0,,arterial catheter implantation,1,days,arterial catheter implantation (for 1 days),107141,arterial catheter implantation (for 1 days),,,,, 3200,"Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28.",body mass,,RS:0000363,F344/NHsd,male,119 days,17,,CMO:0000012,body weight,,,,345,g,11.6297,47.9505,MMO:0000016,body weighing method,,,,,,,control condition,138398,control condition,,,,, 3200,"Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28.",body mass,,RS:0000363,F344/NHsd,male,119 days,14,,CMO:0002781,nose to rump body mass index,,,,7.932467,(g/cm2) x 10,0.222,0.8305,MMO:0000016,body weighing method,,,,,,,control condition,138399,control condition,,,,, 3200,"Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28.",body mass,,RS:0000363,F344/NHsd,male,119 days,14,,CMO:0002780,nose to tail body mass index,,,,2.169182,(g/cm2) x 10,0.0524,0.196,MMO:0000016,body weighing method,,,,,,,control condition,138400,control condition,,,,, 3200,"Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28.",retroperitoneal fat pad mass,,RS:0000363,F344/NHsd,male,119 days,17,,CMO:0000356,retroperitoneal fat pad weight,,,,5.2305884,g,0.4358,1.7968,MMO:0000005,post excision weight measurement,,,,,,,control condition,138401,control condition,,,,, 3200,"Keele GR, etal., Obesity (Silver Spring). 2018 Jan;26(1):213-222. doi: 10.1002/oby.22075. Epub 2017 Nov 28.",epididymal fat pad mass,,RS:0000363,F344/NHsd,male,119 days,17,,CMO:0000357,epididymal fat pad weight,,,,7.987647,g,0.7236,2.9837,MMO:0000005,post excision weight measurement,,,,,,,control condition,138402,control condition,,,,, 3107,"Assadnia S, etal., Circ Res. 1999 Jun 11;84(11):1252-7. doi: 10.1161/01.res.84.11.1252.",iliac artery integrity trait,,RS:0000363,F344/NHsd,male,133 days to 119 days,9,,CMO:0003645,artery neointimal hyperplastic lesion area including tunica media,,,,0.169,mm2,0.0259,0.0777,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,balloon angioplasty,110462,balloon angioplasty,,,,, 3107,"Assadnia S, etal., Circ Res. 1999 Jun 11;84(11):1252-7. doi: 10.1161/01.res.84.11.1252.",iliac artery integrity trait,,RS:0000363,F344/NHsd,male,133 days to 119 days,9,,CMO:0001414,artery neointimal hyperplastic lesion area,,,,0.0494,mm2,0.0051,0.0153,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,balloon angioplasty,110473,balloon angioplasty,,,,, 3107,"Assadnia S, etal., Circ Res. 1999 Jun 11;84(11):1252-7. doi: 10.1161/01.res.84.11.1252.",iliac artery integrity trait,,RS:0000363,F344/NHsd,male,133 days to 119 days,9,,CMO:0001416,artery neointimal hyperplastic lesion area to total wall area ratio,,,,30.9,%,2.86,8.58,MMO:0000220,ex vivo light microscopy with digital image analysis,,0.0,,,,,balloon angioplasty,110484,balloon angioplasty,,,,,